Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

The successful implementation of tyrosine kinase inhibitors (TKIs) for the treatment of
chronic myeloid leukemia (CML) remains a flagship for molecularly targeted therapy in …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with a
characteristic chromosomal translocation called the Philadelphia chromosome. This …

The BCR-ABL1 fusion gene, which causes aberrant kinase activity and uncontrolled cell
proliferation, is the hallmark of chronic myeloid leukemia (CML). The development of …

Patients with newly diagnosed chronic myeloid leukemia (CML) usually received as first-line
treatment a first-or second-generation tyrosine kinase inhibitor (TKI). Although initial …